Press release -

Research details on COPD Drugs Market in China is Projected to Exhibit a CAGR of over 15.56% during 2016 - 2020

COPD Drugs Market in China 2016-2020 Size and Share Published in 2016-06-17 Available for US$ 2500 at


About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

Technavios analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:


Phosphodiesterase-4 (PDE-4) inhibitors


Combination therapies

Technavio's report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Get a Sample Copy of the Report:

Key vendors


Boehringer Ingelheim




Other prominent vendors

Ache Laboratorios Farmaceuticos


Aquinox Pharmaceuticals

Ario Pharma

BioMarck Pharmaceuticals

Gilead Sciences

Mereo BioPharma Group



Pearl Therapeutics


Teva Pharmaceutical Industry

Theravance Biopharma

Theron Pharmaceuticals

Verona Pharma



Market driver

Increase in environmental pollution

For a full, detailed list, view our report

Market challenge

Low diagnosis rate

For a full, detailed list, view our report

Market trend

Increased focus on combination therapies

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.

Inquiry on this report:

Table of Content

PART 01: Executive summary


PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: COPD: An overview

Causes and risk factors




PART 06: China-Country snapshot

Social and economic conditions

Healthcare reform

Healthcare infrastructure

Browse All Healthcare Market Research Reports at:

About ResearchMoz

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives.

Contact Us:

Mr. Nachiket Ghumare, +1-518-621-2074
USA-Canada Toll Free: 866-997-4948


  • Health Care, Health Service


  • china
  • copd drugs
  • healthcare
  • copd drugs market
  • chronic obstructive pulmonary disease
  • copd
  • bronchiectasis
  • emphysema
  • chronic bronchitis
  • refractory asthma
  • non-reversible
  • lung diseases
  • laba
  • ics
  • air pollution